Tedatioxetine (Major Depressive Disorder) Market Key Trends, Vendor Strategies and Analysis 2023

Tedatioxetine (Major Depressive Disorder) Market Size, Share, Global

Trends, Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

Tedatioxetine (Lu AA24530) is being developed by Lundbeck for the treatment of MDD. It is a

multimodal antidepressant and preclinical studies have shown that it acts as a monoamine

enhancer with reuptake inhibition at monoamine transporters, as well as a 5-HT3 and 5-HT2C

receptor antagonist (Lundbeck, press release, July 2, 2009).

For further information on this report, please visit http://www.radiantinsights.com/research/tedatioxetine-major-depressive-disorder-forecastand-market-analysis-to-2023

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,

diagnosis, pathology and treatment guidelines as well as an overview on the competitive

landscape.

- Detailed information on Tedatioxetine including product description, safety and efficacy

profiles as well as a SWOT analysis.

- Sales forecast for Tedatioxetine for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and

Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of...